Published in Brain Res on September 23, 1985
Sex differences in (+)-amphetamine- and (+)-methamphetamine-induced behavioral response in male and female Sprague-Dawley rats. Pharmacol Biochem Behav (2007) 1.18
Dysregulation of D₂-mediated dopamine transmission in monkeys after chronic escalating methamphetamine exposure. J Neurosci (2012) 1.09
Prolonged exposure of rats to intravenous methamphetamine: behavioral and neurochemical characterization. Psychopharmacology (Berl) (2005) 1.02
Methamphetamine self-administration causes persistent striatal dopaminergic alterations and mitigates the deficits caused by a subsequent methamphetamine exposure. J Pharmacol Exp Ther (2011) 0.99
Development of stereotyped behaviors during prolonged escalation of methamphetamine self-administration in rats. Psychopharmacology (Berl) (2012) 0.77
The ancient regulatory-protein family of WD-repeat proteins. Nature (1994) 9.33
Duplicated heavy metal control sequences of the mouse metallothionein-I gene. Proc Natl Acad Sci U S A (1984) 2.69
Toxicological investigations of cases of death involving codeine and dihydrocodeine. Forensic Sci (1977) 2.43
Cu(II) potentiation of alzheimer abeta neurotoxicity. Correlation with cell-free hydrogen peroxide production and metal reduction. J Biol Chem (1999) 2.30
Synthesis and evaluation of a series of novel 2-[(4-chlorophenoxy)methyl]benzimidazoles as selective neuropeptide Y Y1 receptor antagonists. J Med Chem (1998) 2.23
Gas-Liquid Chromatographic Isolation of Cytokinins from Natural Sources: 6-(3-Methyl-2-butenylamino) purine from Agrobacterium Tumefaciens. Plant Physiol (1970) 2.19
Lobeline and nicotine evoke [3H]overflow from rat striatal slices preloaded with [3H]dopamine: differential inhibition of synaptosomal and vesicular [3H]dopamine uptake. J Pharmacol Exp Ther (1997) 2.14
Neuroprotection by caffeine and A(2A) adenosine receptor inactivation in a model of Parkinson's disease. J Neurosci (2001) 1.90
A new class of tyrosine hydroxylase inhibitors and a simple assay of inhibition in vivo. Biochem Pharmacol (1967) 1.54
Methamphetamine rapidly decreases vesicular dopamine uptake. J Neurochem (2000) 1.49
Long-term effects of multiple doses of methamphetamine on tryptophan hydroxylase and tyrosine hydroxylase activity in rat brain. J Pharmacol Exp Ther (1980) 1.49
Time-resolved fluorescence of the two tryptophans in horse liver alcohol dehydrogenase. Biochemistry (1981) 1.48
Midbrain dopaminergic cell loss in Parkinson's disease and MPTP-induced parkinsonism: sparing of calbindin-D28k-containing cells. Ann N Y Acad Sci (1992) 1.46
Differential effects of stimulants on monoaminergic transporters: pharmacological consequences and implications for neurotoxicity. Eur J Pharmacol (2000) 1.46
Peripheral benzodiazepine receptors are colocalized with activated microglia following transient global forebrain ischemia in the rat. J Neurosci (1995) 1.42
Ischemic intervals during warm blood cardioplegia in the canine heart evaluated by phosphorus 31-magnetic resonance spectroscopy. J Thorac Cardiovasc Surg (1997) 1.39
Role of dopamine in the neurotoxic effects of methamphetamine. J Pharmacol Exp Ther (1985) 1.29
Neurotoxicity of the psychedelic amphetamine, methylenedioxymethamphetamine. J Pharmacol Exp Ther (1987) 1.28
Cell specificity and an effect of ras on human metallothionein gene expression. Proc Natl Acad Sci U S A (1986) 1.28
Midbrain dopaminergic neurons in the mouse that contain calbindin-D28k exhibit reduced vulnerability to MPTP-induced neurodegeneration. Neurodegeneration (1996) 1.27
D-1 dopamine receptors in the rat brain: a quantitative autoradiographic analysis. J Neurosci (1986) 1.27
Differential effects of psychostimulants and related agents on dopaminergic and serotonergic transporter function. Eur J Pharmacol (1999) 1.27
Methamphetamine-induced hyperthermia and dopaminergic neurotoxicity in mice: pharmacological profile of protective and nonprotective agents. J Pharmacol Exp Ther (1995) 1.26
Chromosomal location of human metallothionein genes: implications for Menkes' disease. Science (1984) 1.26
Rapid and reversible effects of methamphetamine on dopamine transporters. J Pharmacol Exp Ther (1997) 1.26
Dopamine deficiency in a genetic mouse model of Lesch-Nyhan disease. J Neurosci (1994) 1.22
Amygdalar neuropeptide Y Y1 receptors mediate the anxiolytic-like actions of neuropeptide Y in the social interaction test. Eur J Pharmacol (1999) 1.21
Correlation between the neostriatal content of the 1-methyl-4-phenylpyridinium species and dopaminergic neurotoxicity following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration to several strains of mice. J Pharmacol Exp Ther (1991) 1.20
Regulation of the vesicular monoamine transporter-2: a novel mechanism for cocaine and other psychostimulants. J Pharmacol Exp Ther (2001) 1.20
Cloning and sequence analysis of two monkey metallothionein cDNAs. Gene (1983) 1.20
The neurotoxin MPTP causes degeneration of specific nucleus A8, A9 and A10 dopaminergic neurons in the mouse. Neurodegeneration (1996) 1.20
Role of corticotropin-releasing factor and urocortin within the basolateral amygdala of rats in anxiety and panic responses. Behav Brain Res (1999) 1.19
Structure and expression of two human metallothionein-I isoform genes and a related pseudogene. J Biol Chem (1985) 1.18
Influence of methamphetamine on nigral and striatal tyrosine hydroxylase activity and on striatal dopamine levels. Eur J Pharmacol (1976) 1.15
The effects of 3,4-methylenedioxymethamphetamine (MDMA) and 3,4-methylenedioxyamphetamine (MDA) on monoaminergic systems in the rat brain. Eur J Pharmacol (1986) 1.14
Myosin I heavy-chain genes of Acanthamoeba castellanii: cloning of a second gene and evidence for the existence of a third isoform. Gene (1989) 1.14
Characterization of intracellular elevation of glutathione (GSH) with glutathione monoethyl ester and GSH in brain and neuronal cultures: relevance to Parkinson's disease. Exp Neurol (2006) 1.14
The long-term effects of multiple doses of methamphetamine on neostriatal tryptophan hydroxylase, tyrosine hydroxylase, choline acetyltransferase and glutamate decarboxylase activities. Life Sci (1979) 1.14
Human parvovirus-associated red cell aplasia in the absence of underlying hemolytic anemia. Am J Pediatr Hematol Oncol (1986) 1.13
Methamphetamine-induced rapid and reversible changes in dopamine transporter function: an in vitro model. J Neurosci (2001) 1.13
Cholecystokinin receptors: presence and axonal flow in the rat vagus nerve. Life Sci (1981) 1.13
Rat model of Parkinson's disease: chronic central delivery of 1-methyl-4-phenylpyridinium (MPP+). Exp Neurol (2006) 1.12
Cloning of a human receptor of the NPY receptor family with high affinity for pancreatic polypeptide and peptide YY. J Biol Chem (1995) 1.12
Parallel increases in lipid and protein oxidative markers in several mouse brain regions after methamphetamine treatment. J Neurochem (2001) 1.12
Long-term changes in basal ganglia function after a neurotoxic regimen of methamphetamine. J Pharmacol Exp Ther (2001) 1.11
High affinity GABA receptors-autoradiographic localization. Brain Res (1981) 1.11
Neuropeptide Y receptor subtypes in the basolateral nucleus of the amygdala modulate anxiogenic responses in rats. Neuropharmacology (2002) 1.10
Measurement of human myocardial perfusion by double-gated flow alternating inversion recovery EPI. Magn Reson Med (1999) 1.09
Glycine receptor: light microscopic autoradiographic localization with [3H]strychnine. J Neurosci (1981) 1.08
Autoradiographic localization of high affinity GABA, benzodiazepine, dopaminergic, adrenergic and muscarinic cholinergic receptors in the rat, monkey and human retina. Brain Res (1986) 1.08
Characterization of DorC from Rhodobacter capsulatus, a c-type cytochrome involved in electron transfer to dimethyl sulfoxide reductase. J Biol Chem (1999) 1.08
In vitro and in vivo neurochemical effects of methylenedioxymethamphetamine on striatal monoaminergic systems in the rat brain. Biochem Pharmacol (1987) 1.08
Methylenedioxymethamphetamine: a potentially neurotoxic amphetamine analogue. Eur J Pharmacol (1986) 1.07
Nature of methamphetamine-induced rapid and reversible changes in dopamine transporters. Eur J Pharmacol (1998) 1.07
Mutagenesis of the amino terminus of the alpha subunit of the G protein Go. In vitro characterization of alpha o beta gamma interactions. J Biol Chem (1992) 1.06
Differential distribution of urocortin- and corticotropin-releasing factor-like immunoreactivities in the rat brain. Neuroscience (1999) 1.06
Characterization of the 5-HT2 receptor antagonist MDL 100907 as a putative atypical antipsychotic: behavioral, electrophysiological and neurochemical studies. J Pharmacol Exp Ther (1993) 1.06
Neuronal and behavioural abnormalities in striatal function in DARPP-32-mutant mice. Eur J Neurosci (1999) 1.05
A double-screening method to identify reliable candidate non-synonymous SNPs from chicken EST data. Anim Genet (2003) 1.05
Drugs in fatally injured young male drivers. Public Health Rep (1985) 1.05
Age-dependent differential responses of monoaminergic systems to high doses of methamphetamine. J Neurochem (2000) 1.04
Comparison of the distribution of D-1 and D-2 dopamine receptors in the rat brain. J Chem Neuroanat (1989) 1.03
GABAA receptor subtypes: autoradiographic comparison of GABA, benzodiazepine, and convulsant binding sites in the rat central nervous system. J Chem Neuroanat (1990) 1.03
Methamphetamine-induced rapid decrease in dopamine transporter function: role of dopamine and hyperthermia. J Pharmacol Exp Ther (2000) 1.02
Autoradiographic localization of calcium channels with [125I]omega-conotoxin in rat brain. Eur J Pharmacol (1988) 1.02
The influence of dose and dosing interval on MPTP-induced dopaminergic neurotoxicity in mice. Eur J Pharmacol (1986) 1.01
Roles of D1 and D2 dopamine receptor subtypes in mediating the methamphetamine-induced changes in monoamine systems. J Pharmacol Exp Ther (1986) 1.01
The distribution of histamine H1-receptors in the rat brain: an autoradiographic study. Neuroscience (1981) 1.00
Effects of nicotine on local cerebral glucose utilization in the rat. J Neurosci (1988) 1.00
G-protein alpha o subunit: mutation of conserved cysteines identifies a subunit contact surface and alters GDP affinity. Proc Natl Acad Sci U S A (1993) 0.99
Differential effects of cocaine and methamphetamine on neurotensin/neuromedin N and preprotachykinin messenger RNA expression in unique regions of the striatum. Neuroscience (2001) 0.99
Cocaine-induced increases in vesicular dopamine uptake: role of dopamine receptors. J Pharmacol Exp Ther (2001) 0.99
Analysis of VMAT2 binding after methamphetamine or MPTP treatment: disparity between homogenates and vesicle preparations. J Neurochem (2000) 0.98
Activity of 5,7-dichlorokynurenic acid, a potent antagonist at the N-methyl-D-aspartate receptor-associated glycine binding site. Mol Pharmacol (1990) 0.98
The effects of methamphetamine on serotonin transporter activity: role of dopamine and hyperthermia. J Neurochem (2000) 0.97
The neuropeptide Y Y1 antagonist, 1229U91, a potent agonist for the human pancreatic polypeptide-preferring (NPY Y4) receptor. Peptides (1998) 0.97
Effect of methamphetamine on neurotensin concentrations in rat brain regions. J Pharmacol Exp Ther (1987) 0.97
Computer simulation of magnetic resonance spectra employing homotopy. J Magn Reson (1998) 0.96
The effects of reserpine, alpha-methyltyrosine, and L-3,4-dihydroxyphenylalanine on brain tyrosine transaminase. Proc Natl Acad Sci U S A (1969) 0.96
Endogenous neurotensin antagonizes methamphetamine-enhanced dopaminergic activity. Brain Res (1994) 0.96
Role of the dopamine uptake carrier in the neurochemical response to methamphetamine: effects of amfonelic acid. Eur J Pharmacol (1985) 0.96
Interaction between hyperthermia and oxygen radical formation in the 5-hydroxytryptaminergic response to a single methamphetamine administration. J Pharmacol Exp Ther (1997) 0.96
Methamphetamine treatment rapidly inhibits serotonin, but not glutamate, transporters in rat brain. Brain Res (1998) 0.96
Differential regional effects of methamphetamine on the activities of tryptophan and tyrosine hydroxylase. J Neurochem (1999) 0.96